Bone Biologics Corporation (BBLG) 10-Year Financial Performance & Capital Metrics

BBLG • • Industrial / General

HealthcareMedical DevicesOrthopedic & Musculoskeletal DevicesSpinal Implants & Fusion Systems

AboutBone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.Show more

Revenue $0
EBITDA $161
Net Income -$4M +54.1%
EPS (Diluted) -4.83 +85.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -128.7% +36.3%
ROIC -16515.74%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 11 (bottom 11%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM4.7%

EPS CAGR

10Y-

5Y-

3Y-

TTM-105.72%

ROCE

10Y Avg-105.08%

5Y Avg-105.08%

3Y Avg-134.52%

Latest-132.05%

Peer Comparison

Spinal Implants & Fusion Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GMEDGlobus Medical, Inc.	10.46B	93.89	125.19	60.62%	15.3%	9.63%	3.87%	0.13
TNONTenon Medical, Inc.	10.6M	0.95	-0.08	11.92%	-396.26%	-267.01%		0.07
BBLGBone Biologics Corporation	3M	1.67	-0.35			-65.59%
OFIXOrthofix Medical Inc.	570.24M	14.40	-4.36	7.08%	-14.56%	-26.92%		0.36
XTNTXtant Medical Holdings, Inc.	91M	0.65	-5.42	28.44%	1.32%	3.48%		0.82
ATECAlphatec Holdings, Inc.	2.59B	17.46	-15.45	26.81%	-21.29%	-13.47%		64.65
SIBNSI-BONE, Inc.	762.82M	17.58	-23.44	20.37%	-11.24%	-12.64%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	4.45K	700	96	96	50	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-4.45K	-700	-96	-96	-50	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	0.99%	0.84%	0.86%	0%	0.48%	1%	-	-	-	-
Operating Expenses+	12M	17.85M	2.63M	2.79M	2.45M	825.01K	1.1M	3.67M	9.43M	4.22M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	8.33M	6.25M	3.82M	2.69M	1.35M	484.34K	1.02M	2.09M	2.52M	2.09M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	3.67M	11.6M	-1.19M	104.49K	1.1M	340.67K	82.04K	1.58M	6.91M	2.13M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	567	510	0	0	0	0	0	0
Operating Income+	-12M	-20.41M	-2.63M	-2.79M	-2.45M	-825.01K	-1.1M	-3.67M	-9.43M	-4.22M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-2.98%	-0.7%	0.87%	-0.06%	0.12%	0.66%	-0.34%	-2.32%	-1.57%	0.55%
EBITDA+	-11.99M	-20.41M	-2.63M	-2.79M	-2.45M	-825.01K	-805.58K	-752.91K	0	161
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-2.98%	-0.7%	0.87%	-0.06%	0.12%	0.66%	0.02%	0.07%	1%	-
D&A (Non-Cash Add-back)	4.45K	700	96	96	50	0	0	0	9.43M	4.22M
EBIT	-12M	-23.26M	-2.63M	-2.79M	-2.45M	-825.01K	-805.58K	-752.91K	-8.95M	-4.11M
Net Interest Income+	-1.87M	-2.62M	-4.42M	-1.23M	-975.77K	-997K	-804K	-731.71K	1.87K	55.66K
Interest Income	0	0	0	0	0	998	805	0	1.87K	55.66K
Interest Expense	1.87M	2.62M	4.42M	1.23M	975.77K	998.08K	805.11K	731.71K	0	0
Other Income/Expense	-1.87M	-615K	-4.42M	-1.64M	-975.77K	-998.08K	-507.61K	2.18M	479.57K	106.74K
Pretax Income+	-13.87M	-21.03M	-7.05M	-4.43M	-3.42M	-1.82M	-1.61M	-1.48M	-8.95M	-4.11M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	8.84K	2.24K	1.6K	1.73K	1.6K	1.6K	0	0	0	0
Effective Tax Rate %	1%	1.23%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-13.88M	-25.88M	-7.05M	-4.43M	-3.42M	-1.82M	-1.61M	-1.48M	-8.95M	-4.11M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-2.14%	-0.86%	0.73%	0.37%	0.23%	0.47%	0.12%	0.08%	-5.03%	0.54%
Net Income (Continuing)	-13.88M	-25.88M	-7.05M	-4.43M	-3.42M	-1.82M	-1.61M	-1.48M	-8.95M	-4.11M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-17640.00	-24840.00	-6480.00	-3173.58	-66.97	-35.68	-37.35	-31.20	-34.01	-4.83
EPS Growth %	-0.63%	-0.41%	0.74%	0.51%	0.98%	0.47%	-0.05%	0.16%	-0.09%	0.86%
EPS (Basic)	-17640.00	-24840.00	-6480.00	-3173.58	-66.97	-35.68	-37.35	-31.15	-34.01	-4.83
Diluted Shares Outstanding	791	1.04K	1.08K	1.4K	51.14K	51.14K	43.13K	47.66K	263.14K	1.52M
Basic Shares Outstanding	791	1.04K	1.08K	1.4K	51K	51K	43K	47.6K	263.14K	1.52M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.54M	700.9K	795.51K	1.04M	30.83K	0	6.68M	8.5M	3.74M	3.86M
Cash & Short-Term Investments	1.12M	620.38K	690.28K	955.37K	24.14K	0	6.68M	7.54M	3.03M	3.33M
Cash Only	1.12M	620.38K	690.28K	955.37K	24.14K	0	6.68M	7.54M	3.03M	3.33M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	579.91K	328.84K	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	5.8K	242	146	50	0	0	0	0	0	0
Property, Plant & Equipment	5.8K	242	146	50	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0	0	0
Total Assets+	2.08M	973.09K	795.66K	1.04M	30.83K	0	6.68M	8.5M	3.74M	3.86M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.46%	-0.53%	-0.18%	0.31%	-0.97%	-1%	-	0.27%	-0.56%	0.03%
Total Current Liabilities+	2.15M	1.5M	961.79K	9.64M	578.45K	13.69M	99.91K	2.55M	831.4K	377.71K
Accounts Payable	186.81K	226.52K	216.9K	125.2K	42.88K	465.4K	99.91K	104.79K	360.66K	373.04K
Days Payables Outstanding	15.32K	118.11K	824.68K	476.03K	313.02K	-	-	-	-	-
Short-Term Debt	0	1.2M	0	9M	0	11.72M	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	783.67K	0	0
Other Current Liabilities	1.82M	22.38K	456K	0	253.55K	0	0	1.66M	470.74K	4.67K
Current Ratio	0.72x	0.47x	0.83x	0.11x	0.05x	-	66.81x	3.33x	4.50x	10.22x
Quick Ratio	0.72x	0.47x	0.83x	0.11x	0.05x	-	66.81x	3.33x	4.50x	10.22x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5.08M	7.56M	8.23M	0	11.32M	0	0	0	0	0
Long-Term Debt	5.08M	7.56M	8.23M	0	11.32M	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	7.76M	9.61M	9.19M	9.64M	11.9M	13.69M	99.91K	2.55M	831.4K	377.71K
Total Debt+	5.08M	8.76M	8.23M	9M	11.32M	11.72M	0	0	0	0
Net Debt	4.5M	6.86M	7.54M	8.04M	11.3M	11.72M	-6.68M	-7.54M	-3.03M	-3.33M
Debt / Equity	-	-	-	-	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-20652.99x
Interest Coverage	-6.41x	-7.80x	-0.59x	-2.27x	-2.51x	-0.83x	-1.37x	-5.01x	-	-
Total Equity+	-5.68M	-8.63M	-8.4M	-8.6M	-11.87M	-13.69M	6.58M	5.95M	2.91M	3.48M
Equity Growth %	-0.54%	-0.52%	0.03%	-0.02%	-0.38%	-0.15%	1.48%	-0.1%	-0.51%	0.2%
Book Value per Share	-7185.57	-8262.25	-7766.72	-6159.15	-232.07	-267.75	152.47	124.79	11.05	2.30
Total Shareholders' Equity	-5.68M	-8.36M	-8.4M	-8.6M	-11.87M	-13.69M	6.58M	5.95M	2.91M	3.48M
Common Stock	32.21K	38.83K	43.28K	26.45K	30.68K	30.68K	10.35K	15.3K	534	2.95K
Retained Earnings	-25.91M	-52.13M	-59.19M	-63.62M	-67.04M	-68.86M	-70.48M	-71.96M	-80.91M	-85.02M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3.98K	1.82M	-357	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.55M	-7.33M	-3.33M	-4.1M	-3.25M	-426.93K	-1.23M	-3.57M	-9.56M	-4.12M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.29%	-1.07%	0.55%	-0.23%	0.21%	0.87%	-1.88%	-1.9%	-1.68%	0.57%
Net Income	-13.88M	-21.03M	-7.05M	-4.43M	-3.42M	-1.82M	-1.61M	-1.48M	-8.95M	-4.11M
Depreciation & Amortization	4.45K	700	96	96	50	0	0	0	0	0
Stock-Based Compensation	3.7M	3.46M	-584.03K	516.64K	49.69K	60K	207.03K	266.63K	152.6K	188.82K
Deferred Taxes	498.87K	6.09M	0	-716.79K	-277.75K	0	0	0	0	0
Other Non-Cash Items	6.04M	4.01M	3.37M	380.03K	257.81K	938.08K	495.55K	-2.18M	-892.69K	-51.08K
Working Capital Changes	87.98K	144.48K	938.74K	145.54K	143.78K	399.68K	-320.49K	-168.37K	132.92K	-150.25K
Change in Receivables	75	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	194.46K	73.34K	0	-66.91K	-64.82K	333K	-365.49K	788.55K	255.88K	89.78K
Cash from Investing+	-504	0	0	0	0	0	0	0	0	0
Capital Expenditures	-504	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	2M	6.83M	3.4M	4.37M	2.32M	402.79K	7.9M	4.43M	5.04M	4.42M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	-3.21M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	1.25M	0	0	0	0	0	0	0	5.02M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.55M	-7.33M	-3.33M	-4.1M	-3.25M	-426.93K	-1.23M	-3.57M	-9.56M	-4.12M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.28%	-1.07%	0.55%	-0.23%	0.21%	0.87%	-1.88%	-1.9%	-1.68%	0.57%
FCF per Share	-4485.44	-7012.29	-3080.57	-2940.46	-63.58	-8.35	-28.49	-74.84	-36.32	-2.72
FCF Conversion (FCF/Net Income)	0.26x	0.28x	0.47x	0.93x	0.95x	0.23x	0.76x	2.40x	1.07x	1.00x
Interest Paid	544.71K	751.31K	516.38K	821.96K	717.97K	0	0	0	0	0
Taxes Paid	8.84K	2.24K	1.6K	1.73K	1.6K	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-	-24.5%	-23.71%	-202.15%	-128.7%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-	-	-	-16515.74%
Interest Coverage	-6.41x	-7.80x	-0.59x	-2.27x	-2.51x	-0.83x	-1.37x	-5.01x	-	-
FCF Conversion	0.26x	0.28x	0.47x	0.93x	0.95x	0.23x	0.76x	2.40x	1.07x	1.00x

Frequently Asked Questions

Growth & Financials

Bone Biologics Corporation (BBLG) grew revenue by 0.0% over the past year. Growth has been modest.

Bone Biologics Corporation (BBLG) reported a net loss of $3.9M for fiscal year 2024.

Dividend & Returns

Yes, Bone Biologics Corporation (BBLG) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.

Bone Biologics Corporation (BBLG) has a return on equity (ROE) of -128.7%. Negative ROE indicates the company is unprofitable.

Bone Biologics Corporation (BBLG) had negative free cash flow of $3.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Bone Biologics Corporation (BBLG) 10-Year Financial Performance & Capital Metrics

BBLG • • Industrial / General

HealthcareMedical DevicesOrthopedic & Musculoskeletal DevicesSpinal Implants & Fusion Systems

Revenue $0
EBITDA $161
Net Income -$4M +54.1%
EPS (Diluted) -4.83 +85.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -128.7% +36.3%
ROIC -16515.74%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 11 (bottom 11%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM4.7%

EPS CAGR

10Y-

5Y-

3Y-

TTM-105.72%

ROCE

10Y Avg-105.08%

5Y Avg-105.08%

3Y Avg-134.52%

Latest-132.05%

Peer Comparison

Spinal Implants & Fusion Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GMEDGlobus Medical, Inc.	10.46B	93.89	125.19	60.62%	15.3%	9.63%	3.87%	0.13
TNONTenon Medical, Inc.	10.6M	0.95	-0.08	11.92%	-396.26%	-267.01%		0.07
BBLGBone Biologics Corporation	3M	1.67	-0.35			-65.59%
OFIXOrthofix Medical Inc.	570.24M	14.40	-4.36	7.08%	-14.56%	-26.92%		0.36
XTNTXtant Medical Holdings, Inc.	91M	0.65	-5.42	28.44%	1.32%	3.48%		0.82
ATECAlphatec Holdings, Inc.	2.59B	17.46	-15.45	26.81%	-21.29%	-13.47%		64.65
SIBNSI-BONE, Inc.	762.82M	17.58	-23.44	20.37%	-11.24%	-12.64%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	4.45K	700	96	96	50	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-4.45K	-700	-96	-96	-50	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	0.99%	0.84%	0.86%	0%	0.48%	1%	-	-	-	-
Operating Expenses+	12M	17.85M	2.63M	2.79M	2.45M	825.01K	1.1M	3.67M	9.43M	4.22M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	8.33M	6.25M	3.82M	2.69M	1.35M	484.34K	1.02M	2.09M	2.52M	2.09M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	3.67M	11.6M	-1.19M	104.49K	1.1M	340.67K	82.04K	1.58M	6.91M	2.13M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	567	510	0	0	0	0	0	0
Operating Income+	-12M	-20.41M	-2.63M	-2.79M	-2.45M	-825.01K	-1.1M	-3.67M	-9.43M	-4.22M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-2.98%	-0.7%	0.87%	-0.06%	0.12%	0.66%	-0.34%	-2.32%	-1.57%	0.55%
EBITDA+	-11.99M	-20.41M	-2.63M	-2.79M	-2.45M	-825.01K	-805.58K	-752.91K	0	161
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-2.98%	-0.7%	0.87%	-0.06%	0.12%	0.66%	0.02%	0.07%	1%	-
D&A (Non-Cash Add-back)	4.45K	700	96	96	50	0	0	0	9.43M	4.22M
EBIT	-12M	-23.26M	-2.63M	-2.79M	-2.45M	-825.01K	-805.58K	-752.91K	-8.95M	-4.11M
Net Interest Income+	-1.87M	-2.62M	-4.42M	-1.23M	-975.77K	-997K	-804K	-731.71K	1.87K	55.66K
Interest Income	0	0	0	0	0	998	805	0	1.87K	55.66K
Interest Expense	1.87M	2.62M	4.42M	1.23M	975.77K	998.08K	805.11K	731.71K	0	0
Other Income/Expense	-1.87M	-615K	-4.42M	-1.64M	-975.77K	-998.08K	-507.61K	2.18M	479.57K	106.74K
Pretax Income+	-13.87M	-21.03M	-7.05M	-4.43M	-3.42M	-1.82M	-1.61M	-1.48M	-8.95M	-4.11M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	8.84K	2.24K	1.6K	1.73K	1.6K	1.6K	0	0	0	0
Effective Tax Rate %	1%	1.23%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-13.88M	-25.88M	-7.05M	-4.43M	-3.42M	-1.82M	-1.61M	-1.48M	-8.95M	-4.11M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-2.14%	-0.86%	0.73%	0.37%	0.23%	0.47%	0.12%	0.08%	-5.03%	0.54%
Net Income (Continuing)	-13.88M	-25.88M	-7.05M	-4.43M	-3.42M	-1.82M	-1.61M	-1.48M	-8.95M	-4.11M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-17640.00	-24840.00	-6480.00	-3173.58	-66.97	-35.68	-37.35	-31.20	-34.01	-4.83
EPS Growth %	-0.63%	-0.41%	0.74%	0.51%	0.98%	0.47%	-0.05%	0.16%	-0.09%	0.86%
EPS (Basic)	-17640.00	-24840.00	-6480.00	-3173.58	-66.97	-35.68	-37.35	-31.15	-34.01	-4.83
Diluted Shares Outstanding	791	1.04K	1.08K	1.4K	51.14K	51.14K	43.13K	47.66K	263.14K	1.52M
Basic Shares Outstanding	791	1.04K	1.08K	1.4K	51K	51K	43K	47.6K	263.14K	1.52M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.54M	700.9K	795.51K	1.04M	30.83K	0	6.68M	8.5M	3.74M	3.86M
Cash & Short-Term Investments	1.12M	620.38K	690.28K	955.37K	24.14K	0	6.68M	7.54M	3.03M	3.33M
Cash Only	1.12M	620.38K	690.28K	955.37K	24.14K	0	6.68M	7.54M	3.03M	3.33M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	579.91K	328.84K	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	5.8K	242	146	50	0	0	0	0	0	0
Property, Plant & Equipment	5.8K	242	146	50	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0	0	0
Total Assets+	2.08M	973.09K	795.66K	1.04M	30.83K	0	6.68M	8.5M	3.74M	3.86M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.46%	-0.53%	-0.18%	0.31%	-0.97%	-1%	-	0.27%	-0.56%	0.03%
Total Current Liabilities+	2.15M	1.5M	961.79K	9.64M	578.45K	13.69M	99.91K	2.55M	831.4K	377.71K
Accounts Payable	186.81K	226.52K	216.9K	125.2K	42.88K	465.4K	99.91K	104.79K	360.66K	373.04K
Days Payables Outstanding	15.32K	118.11K	824.68K	476.03K	313.02K	-	-	-	-	-
Short-Term Debt	0	1.2M	0	9M	0	11.72M	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	783.67K	0	0
Other Current Liabilities	1.82M	22.38K	456K	0	253.55K	0	0	1.66M	470.74K	4.67K
Current Ratio	0.72x	0.47x	0.83x	0.11x	0.05x	-	66.81x	3.33x	4.50x	10.22x
Quick Ratio	0.72x	0.47x	0.83x	0.11x	0.05x	-	66.81x	3.33x	4.50x	10.22x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5.08M	7.56M	8.23M	0	11.32M	0	0	0	0	0
Long-Term Debt	5.08M	7.56M	8.23M	0	11.32M	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	7.76M	9.61M	9.19M	9.64M	11.9M	13.69M	99.91K	2.55M	831.4K	377.71K
Total Debt+	5.08M	8.76M	8.23M	9M	11.32M	11.72M	0	0	0	0
Net Debt	4.5M	6.86M	7.54M	8.04M	11.3M	11.72M	-6.68M	-7.54M	-3.03M	-3.33M
Debt / Equity	-	-	-	-	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-20652.99x
Interest Coverage	-6.41x	-7.80x	-0.59x	-2.27x	-2.51x	-0.83x	-1.37x	-5.01x	-	-
Total Equity+	-5.68M	-8.63M	-8.4M	-8.6M	-11.87M	-13.69M	6.58M	5.95M	2.91M	3.48M
Equity Growth %	-0.54%	-0.52%	0.03%	-0.02%	-0.38%	-0.15%	1.48%	-0.1%	-0.51%	0.2%
Book Value per Share	-7185.57	-8262.25	-7766.72	-6159.15	-232.07	-267.75	152.47	124.79	11.05	2.30
Total Shareholders' Equity	-5.68M	-8.36M	-8.4M	-8.6M	-11.87M	-13.69M	6.58M	5.95M	2.91M	3.48M
Common Stock	32.21K	38.83K	43.28K	26.45K	30.68K	30.68K	10.35K	15.3K	534	2.95K
Retained Earnings	-25.91M	-52.13M	-59.19M	-63.62M	-67.04M	-68.86M	-70.48M	-71.96M	-80.91M	-85.02M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3.98K	1.82M	-357	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.55M	-7.33M	-3.33M	-4.1M	-3.25M	-426.93K	-1.23M	-3.57M	-9.56M	-4.12M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.29%	-1.07%	0.55%	-0.23%	0.21%	0.87%	-1.88%	-1.9%	-1.68%	0.57%
Net Income	-13.88M	-21.03M	-7.05M	-4.43M	-3.42M	-1.82M	-1.61M	-1.48M	-8.95M	-4.11M
Depreciation & Amortization	4.45K	700	96	96	50	0	0	0	0	0
Stock-Based Compensation	3.7M	3.46M	-584.03K	516.64K	49.69K	60K	207.03K	266.63K	152.6K	188.82K
Deferred Taxes	498.87K	6.09M	0	-716.79K	-277.75K	0	0	0	0	0
Other Non-Cash Items	6.04M	4.01M	3.37M	380.03K	257.81K	938.08K	495.55K	-2.18M	-892.69K	-51.08K
Working Capital Changes	87.98K	144.48K	938.74K	145.54K	143.78K	399.68K	-320.49K	-168.37K	132.92K	-150.25K
Change in Receivables	75	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	194.46K	73.34K	0	-66.91K	-64.82K	333K	-365.49K	788.55K	255.88K	89.78K
Cash from Investing+	-504	0	0	0	0	0	0	0	0	0
Capital Expenditures	-504	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	2M	6.83M	3.4M	4.37M	2.32M	402.79K	7.9M	4.43M	5.04M	4.42M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	-3.21M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	1.25M	0	0	0	0	0	0	0	5.02M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.55M	-7.33M	-3.33M	-4.1M	-3.25M	-426.93K	-1.23M	-3.57M	-9.56M	-4.12M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.28%	-1.07%	0.55%	-0.23%	0.21%	0.87%	-1.88%	-1.9%	-1.68%	0.57%
FCF per Share	-4485.44	-7012.29	-3080.57	-2940.46	-63.58	-8.35	-28.49	-74.84	-36.32	-2.72
FCF Conversion (FCF/Net Income)	0.26x	0.28x	0.47x	0.93x	0.95x	0.23x	0.76x	2.40x	1.07x	1.00x
Interest Paid	544.71K	751.31K	516.38K	821.96K	717.97K	0	0	0	0	0
Taxes Paid	8.84K	2.24K	1.6K	1.73K	1.6K	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-	-24.5%	-23.71%	-202.15%	-128.7%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-	-	-	-16515.74%
Interest Coverage	-6.41x	-7.80x	-0.59x	-2.27x	-2.51x	-0.83x	-1.37x	-5.01x	-	-
FCF Conversion	0.26x	0.28x	0.47x	0.93x	0.95x	0.23x	0.76x	2.40x	1.07x	1.00x

Frequently Asked Questions

Growth & Financials

Bone Biologics Corporation (BBLG) grew revenue by 0.0% over the past year. Growth has been modest.

Bone Biologics Corporation (BBLG) reported a net loss of $3.9M for fiscal year 2024.

Dividend & Returns

Yes, Bone Biologics Corporation (BBLG) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.

Bone Biologics Corporation (BBLG) has a return on equity (ROE) of -128.7%. Negative ROE indicates the company is unprofitable.

Bone Biologics Corporation (BBLG) had negative free cash flow of $3.3M in fiscal year 2024, likely due to heavy capital investments.